TREM-1 Gene Polymorphisms

计划入组 160 人 · 首次发布于 2011 年 12 月 13 日

TREM-1 Pathway Activation in COVID-19

计划入组 830 人 · 首次发布于 2020 年 9 月 10 日

Trem-1 and Ultraviolet Radiation-induced Immune Suppression

计划入组 70 人 · 首次发布于 2021 年 8 月 25 日

TREM-1 inhibitor (SignaBlok)

TREM-1 Antibody(Boehringer Ingelheim)

TREM-1 antibody (autoimmune disease)

NHI-1

United States

Xi'an No.1 Hospital

China

ALPHA-1 FOUNDATION, INC.

United States

FDA Grants Orphan Drug Designation to SignaBlok's TREM-1 Inhibitor for Retinopathy of Prematurity

Ligand-Independent Strategies May Overcome Challenges in TREM-1 and TREM-2 Inhibition

TREM-1 Emerges as Master Amplifier of Inflammation, Offering New Therapeutic Avenue for Sepsis, Arthritis, and Neurodegenerative Diseases